options

BingX New Dual Investment Offering Sees $1M in User Participation

PANAMA CITY, June 20, 2025 /PRNewswire/ -- BingX, a leading cryptocurrency exchange and Web3 AI company, has officially launched its…

1 month ago

Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241

PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical…

1 month ago

Avricore Grants Options

June 14, 2025 01:05 ET  | Source: Avricore Health Inc. VANCOUVER, British Columbia, June 14, 2025 (GLOBE NEWSWIRE) -- AVRICORE…

1 month ago

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences…

1 month ago

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 13, 2025 16:01 ET  | Source: Nurix Therapeutics, Inc. SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics,…

1 month ago

TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 06, 2025 16:05 ET  | Source: TELA Bio, Inc. MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio,…

2 months ago

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13)…

2 months ago

Fibe Unveils Digital FDs, Strengthening Its Role as a One-Stop Financial Partner

Enables investments without a linked savings account, with options from top banks and NBFCsOffers up to 9.1% interest and smart…

2 months ago

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TE

Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED)…

2 months ago